Prenatal exposure to methyldopa leading to hypertensive crisis and cardiac failure in a neonate.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 24777213.
- Also identified by DOI 10.1542/peds.2013-1438.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 2-week-old infant with normal intracardiac anatomy presented to the emergency department in a hypertensive crisis with acute cardiac failure. Despite extensive evaluation, no underlying disease was found. The patient's hypertension and cardiac dysfunction resolved after 1 week of supportive care in the PICU, and she was discharged within 2 weeks of presentation. The patient's history revealed transplacental exposure to the α-adrenergic agonist methyldopa for 10 weeks before delivery. Her age at presentation and the self-limited nature of cardiac sequelae with complete resolution of cardiac dysfunction suggest withdrawal effects from this exposure. Whereas the rebound hypertensive effects of α-adrenergic agonists are well established in the adult population, this report shows an unusual adverse outcome of in utero exposure to methyldopa.
Medical subject headings
- Adrenergic Agonists
- Heart Failure
- Hypertension
- Hypertension, Pregnancy-Induced
- Methyldopa
- Prenatal Exposure Delayed Effects
- Substance Withdrawal Syndrome